DUBAI, UAE, Aug. 13, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, issued its latest TradFi report, highlighting gold’s enduring safe-haven appeal as investors prepare for major macroeconomic events. Following a record high earlier this year, gold is trading in a narrow range with neutral momentum, signaling potential for a decisive move as inflation data, tariff deadlines, and central bank policy decisions approach.

Key Highlights

• All-Time High: Gold touched a record $3,500 on April 22, 2025, and is now consolidating near $3,365.
• Defined Range: Since May 20, trading has remained within $3,274 support and $3,443 resistance.
• Neutral Momentum: Daily RSI stands at 50, with MACD flat, indicating balanced market forces but rising breakout potential.
• Macro Watch: The August 12 inflation report, tariff deadlines, and the September 17 Federal Reserve decision could spark sharp price swings.
• Labor Market Weakness: The latest U.S. jobs report revealed a significant hiring slowdown, fueling rate-cut expectations.
• Diversification Play: Silver is holding at $40, with potential to retest its $50 all-time high.

Gold’s consolidation comes as macroeconomic uncertainty builds, with weakening labor data and trade tensions adding to market caution. Technical patterns point to stored momentum, while silver’s parallel strength offers an additional diversification opportunity for investors. The weeks ahead may prove pivotal in determining the next phase of price action for both metals.

#Bybit / #TheCryptoArk /#BybitResearch

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

KUALA LUMPUR, Malaysia, Aug. 13, 2025 /PRNewswire/ — The ASEAN TVET Conference (ASEAN TVET), a flagship platform under the ASEAN Year of Skills (AYOS) 2025, opened today with a united call for the region to prepare its workforce for advanced digitalisation and the green transition, paving the way for a future-ready TVET ecosystem.

Jointly organised by the Human Resource Development Corporation (HRD Corp) and Skills Development Fund Corporation Malaysia (PTPK), both under the Ministry of Human Resources (KESUMA), the conference gathered about 1,500 policymakers, industry leaders, TVET providers and educators at the World Trade Centre Kuala Lumpur.

Over two days, the event will drive collaboration on advancing Technical and Vocational Education and Training (TVET) as a catalyst for inclusive digital and green transitions. 57 exhibitors showcased innovations, training solutions and technologies that support these skills.

Officiating the event, The Right Honourable Dato’ Seri Dr. Ahmad Zahid bin Hamidi, Deputy Prime Minister of Malaysia, Minister of Rural and Regional Development, and Chairman of National TVET Council, called for ASEAN to address rising demand for digital and green talent.

“This conference must spark policies that meet market needs, make employers true partners and fast-track cutting-edge learning. This is how ASEAN will shape a workforce that is inclusive, future-ready and poised to lead the global TVET industry,” he said.

He proposed establishing an ASEAN Green and Digital Skills Taskforce to unite the region in concrete actions and measurable targets.

The Honourable Steven Sim Chee Keong, Minister of Human Resources, stressed ASEAN’s opportunity to lead in the digital and green economy through collaboration and inclusive skills development.

“In an age when AI can do the thinking, the world still needs those who can build, repair, operate, supervise and organise. These elements will outlast the hype cycles of technology. Skills training is the currency of the day,” he said, calling for greater synergy in a common certification framework and mutual recognition to advance the ASEAN skills market.

Joining virtually, His Excellency Dr. Kao Kim Hourn, Secretary-General of ASEAN, urged stronger partnerships between training institutions and industry to accelerate green skills development.

“Our efforts must ensure we lead, not follow, in the global green economy,” he said, warning that without decisive action, skills gaps could slow economic progress.

The conference, themed ‘Advancing Digital and Green Transformations through an Inclusive and Future-Ready TVET System’, examined integrating sustainability into skills, and training, for a just transition.

Representing International Labour Organization (ILO), Kaori Nakamura-Osaka, Assistant Director General and Regional Director for Asia and the Pacific, said, “TVET holds unique potential to drive the digital and green transformation. Skills training must be aligned to these transitions, with emerging technologies embedded into learning. No one can be left behind.”

Upcoming AYOS events include the National Human Capital Conference & Exhibition (NHCCE), Global Skills Forum (GSF) and the ASEAN Forum of Manpower Ministers for Human Capital Development (AFMM-HCD), continuing Malaysia’s push for bold collaborations, stronger industry engagement and embedding environmental sustainability into skills systems.

For more information, visit www.aseanyearofskills.org.

Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).

FORT WORTH, Texas, Aug. 13, 2025 /PRNewswire/ — The Rainwater Charitable Foundation, one of the largest independent funders of primary tauopathy research, in collaboration with the Aging Mind Foundation, the Alzheimer’s Association, and CurePSP, announced today $2.5 million in grants to fund five innovative research projects over the course of two years emerging from the second annual Tauopathy Challenge Workshop.

The Tauopathy Challenge Workshop is a funding program that convenes interdisciplinary experts around a single topic, addressing unmet needs in primary tauopathies. By funding innovative research, it aims to support the development of treatments for these debilitating neurodegenerative diseases, such as Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).

Growing in size and impact since its inception in 2023, the Tauopathy Challenge Workshop has awarded $4.5 million to support novel, mechanism-focused research aimed at uncovering new therapeutic and biomarker targets for these tau-driven neurodegenerative diseases. This year, five groundbreaking projects will be funded and led by esteemed international researchers:

• Eleanor Drummond, PhD, University of Sydney (Awarded $500,000): This research aims to uncover how abnormal protein aggregation beyond tau contributes to primary tauopathies, specifically PSP, CBD, and Pick’s disease. Using advanced molecular techniques, Dr. Drummond will identify proteins in the human brain prone to forming pathological aggregates and determine whether these changes are shared across different tauopathies. By mapping the location of these proteins in brain tissue and testing whether tau drives their aggregation, the study seeks to clarify disease mechanisms, identify biomarkers, and explore whether these processes can be reversed in cell models—ultimately guiding future therapeutic strategies.
• Leonard Petrucelli, PhD, Mayo Clinic (Awarded $500,000): This research explores whether lysosomal transmembrane protein 106B (TMEM106B) fibrils promote tau seeding and worsen PSP symptoms, by analyzing post-mortem brain samples and assessing correlations between protein levels, genetic variants, and disease severity. Using innovative tools in human neurons and mouse models, Dr. Petrucelli and his co-investigator, Dr. Michael Ward (National Institutes of Health), will test whether TMEM106B fibrils directly influence tau pathology and lysosomal dysfunction, potentially uncovering new mechanisms and therapeutic targets for PSP.
• Vijay Rangachari, PhD, The University of Southern Mississippi (Awarded $500,000): This research examines the potential interaction between two amyloid-forming proteins—transactive response DNA binding protein 43 kDa (TDP-43) and tau—in neurodegenerative diseases such as PSP and frontotemporal lobar degeneration (FTLD). While both proteins are known to independently form toxic aggregates, the work explores whether they can co-aggregate into “hybrid amyloids” with unique structures and pathological effects. Dr. Rangachari aims to confirm the presence of these deposits in human brain tissue, understand their molecular characteristics, and assess their role in neuronal dysfunction—with the hope of developing antibodies to detect these toxic agents in the brain.
• Wilfried Rossoll, PhD, Mayo Clinic (Awarded $500,000): This research aims to uncover how TDP-43 co-pathology influences tau pathology and contributes to neurodegeneration in PSP and CBD. By leveraging both innovative spatial proteomics discovery approaches in human post-mortem brain tissue and mechanistic studies in mouse brain tissue culture models, Dr. Rossoll will explore how these proteins interact and affect overall disease progression. Insights gained will pave the way for stronger tools for studying neurodegenerative disorders and developing effective treatments.
• Mikael Simons, MD, Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE (German Center for Neurodegenerative Diseases) (Awarded $500,000): This research investigates how non-neuronal cells, particularly glial cells like oligodendrocytes, and factors such as myelin damage and lipoproteins (particularly ApoE), contribute to tau aggregation and propagation. Using advanced imaging, biochemical assays, and both mouse models and human brain tissue, Dr. Simons aims to uncover whether disruptions in myelin and lipid transport systems play a critical role in tau pathology. The goal is to deepen understanding of tau-related disorders and identify potential therapeutic targets.

“We’re encouraged to see growing momentum around the Tauopathy Challenge Workshop, with partners such as the Aging Mind Foundation, the Alzheimer’s Association, and CurePSP joining our mission to support these novel, high impact proposals,” said Jeremy Smith, President of the Rainwater Charitable Foundation. “Given the current constraints on research funding, our commitment remains steadfast in advancing primary tauopathy research. The insights gained from this workshop have the potential to significantly impact broader neurodegenerative disease research, bringing us closer to meaningful treatments for those affected.”

The 2026 Tauopathy Challenge Workshop is open to all researchers through a letter of intent process, with applications for the next workshop open through September 2, 2025. The 2026 session is focused on exploring the structural and thermodynamic properties of tau and its interactions with other pathologies. Winners will collectively receive over $2 million to fund their proposed neurodegenerative research.

About the Rainwater Charitable Foundation’s Medical Research
The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater. When Richard was diagnosed with a rare neurodegenerative disease and primary tauopathy called Progressive Supranuclear Palsy (PSP), the RCF expanded its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders. The RCF Medical Research Team supports this focus by managing the Tau Consortium, the Rainwater Prize Program and the Tauopathy Challenge Workshop. With over $140 million invested in medical research to date, the RCF has helped to advance eight treatments into human trials. Currently the RCF supports a range of programs, including a focus on family economic security, medical research and other worthy causes. For more information, please visit rainwatercharitablefoundation.org. 

About the Aging Mind Foundation
The Aging Mind Foundation (AMF) raises money to fund scientific research that seeks the causes of Alzheimer’s disease and other types of dementia. Since 2013, AMF has awarded significant grants to support innovative research with the ultimate goal of discovering a cure. By investing in discovery and innovation, AMF is committed to reducing the devastating impact of dementia on individuals, families, and communities. Aging Mind Foundation is a project of Players Philanthropy Fund, Inc., a Texas nonprofit corporation recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178). To learn more, visit www.agingmindfoundation.org.

About the Alzheimer’s Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call 800.272.3900.

About CurePSP
CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). As a catalyst for new treatments and a cure, CurePSP establishes important partnerships and funds critical research internationally. Through its advocacy and support efforts, CurePSP enhances education, care delivery and quality of life for people living with PSP, CBD and MSA and their families. Science, community and hope are at the heart of CurePSP’s mission and all its services. CurePSP is a registered 501(c)(3) charity within the United States (EIN: 52-1704978). For more information, please visit www.psp.org.

Corporate Contact: 
Jordan Brainerd 
The Rainwater Charitable Foundation
jbrainerd@rainwatercf.org 
(817) 820-2708 

Media Contact:
Kerry Sinclair
Spectrum Science
ksinclair@spectrumscience.com 
(202) 587-1507

Logo – https://laotiantimes.com/wp-content/uploads/2025/08/tauopathy_challenge_workshop_logo.jpg 

– Partnership to accelerate expansion in Asian and European markets and advance global data protection standards –

SEOUL, South Korea, Aug. 13, 2025 /PRNewswire/ — O.NE People, a leading South Korean provider of AI-powered personal data protection automation solutions, has signed a strategic Memorandum of Understanding (MOU) with Prighter GmbH, a Vienna-based global leader in privacy compliance and representative services.

The signing ceremony, held at O.NE People’s Seoul headquarters, brought together Ayoung Cho, CEO of O.NE People, and Andreas Mätzler, CEO of Prighter, to formalize the partnership. The agreement sets the stage for a close, long-term collaboration in the global personal data protection and compliance sector.

Through this alliance, the two companies will:

• Integrate their solutions and services to accelerate global market entry
• Collaborate on identifying and executing joint projects in Asia and Europe
• Co-host marketing campaigns and educational seminars on data privacy and compliance

O.NE People’s flagship solution, CATCHSECU, is a SaaS platform that automates the full privacy compliance process for personal data—from collection to secure disposal—helping organizations meet the world’s most stringent privacy regulations. Trusted by more than 3,000 corporate and public sector clients, CATCHSECU enables businesses to streamline compliance, reduce personal information related risks, and enhance operational efficiency.

Prighter specializes in providing local representative services under the EU’s General Data Protection Regulation (GDPR) and other national data protection laws. With operations in the UK, Switzerland, Turkey, and China, Prighter’s extensive global network supports organizations in meeting complex regulatory requirements.

“Partnering with Prighter gives us the foundation to bring CATCHSECU to even more businesses around the globe,” said Ayoung Cho, CEO of O.NE People. “By leveraging our combined expertise, we aim to strengthen and expand the global data privacy ecosystem.”

“We are excited to work with O.NE People, one of South Korea’s most innovative data privacy solution providers,” said Andreas Mätzler, CEO of Prighter. “Together, we can deliver meaningful impact across Asia and the broader global data protection landscape.”

About O.NE People

Founded in 2018, O.NE People helps organizations comply with personal data protection regulations through its AI-powered SaaS platform, CATCHSECU. The solution automates the entire personal data lifecycle, including consent form generation, encryption, masking, automated disposal, and access control. Serving more than 3,000 organizations worldwide, O.NE People enables clients to minimize legal risks and maximize operational efficiency.

About Prighter GmbH

Headquartered in Vienna, Austria, Prighter GmbH is a global privacy compliance and representative services provider. The company offers local representation under the EU GDPR and other data protection frameworks, serving clients in key markets including the UK, Switzerland, Turkey, and China. Prighter supports a diverse international customer base with expertise and a robust global network.

– BioDlink’s bevacizumab injection secures marketing authorization in Colombia and Pakistan following its recent approval in Nigeria, marking key regulatory milestones in high-need emerging markets.

– GMP certification in Brazil, Colombia, and Argentina spans the top three most populous countries in South America, collectively representing 71.4% of the continent’s population.

– Backed by a globally recognized quality system and a strong track record in monoclonal antibody, ADC/XDC, biosimilar development and manufacturing, BioDlink, in partnership with Kexing BioPharm is fast-tracking access to high-quality oncology biosimilars in underserved regions.

SUZHOU, China, Aug. 13, 2025 /PRNewswire/ — BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP). This development underscores its mission to improve access to critical cancer therapies worldwide.

Following GMP certification in China, Colombia, Brazil, Argentina, Egypt, Indonesia and Pakistan, Kexing BioPharm, the global licensee for bevacizumab injection in emerging markets, has initiated regulatory filings in 35 countries in close collaboration with BioDlink. GMP certification in Brazil, Colombia and Argentina covers the top three most populous countries in South America, representing 71.4% of the continent’s population ^[1].

BioDlink’s manufacturing facilities span 50,000 square meters and have passed antibody drug and ADC EU-QP inspection (including zero-defect) five times in the past four years. BioDlink’s global-quality system is robust, delivering over 100 clinical projects with development, clinical filings, and manufacturing services worldwide, including Europe and the U.S.

Meeting unmet needs in public health

Colombia and Pakistan are key pharmaceutical markets in South America and South Asia respectively. Both nations see a trend toward an increase in the incidence of colorectal cancer. The launch of bevacizumab injection seeks to lower the cost of treatment for both public health systems and patients, while maintaining rigorous global quality standards.

Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is widely used in the treatment of various cancers, including metastatic colorectal cancer (mCRC) and metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC). According to industry estimates, bevacizumab injection achieved global sales of USD 8.5 billion in 2023^[2]. 

“Cancer incidence is rising sharply, especially colorectal cancer^[3], which has seen a global increase in early-onset cases in middle- and low‑income countries,” said Dr. Jun Liu, CEO and Executive Director of BioDlink. “With our partnership with Kexing Biopharm, we are committed to serving South American and other emerging markets and combat colorectal and lung cancers, the top two leading causes of cancer-related deaths worldwide ^[4].”

Since BioDlink signed an international commercialization agreement with Kexing BioPharm in early 2022, both parties have achieved an efficient closed-loop “R&D-manufacturing-access” model. BioDlink focuses on ensuring international manufacturing and supply chain robustness, while Kexing BioPharm leverages its global channels to drive localized market access efficiently.

BioDlink and Kexing BioPharm share an operational philosophy of “leading with quality and building on compliance” to focus on emerging markets such as South America, South Asia, Southeast Asia and Africa. Both companies look forward to deepening their global collaboration to fulfill a shared mission of advancing global healthcare.

About BioDlink

BioDlink, a leading global Contract Development and Manufacturing Organization (CDMO) specializing in biologics, is committed to being the trusted partner of choice for biopharmaceutical innovators worldwide. Leveraging our advanced one-base integrated platform, BioDlink delivers end-to-end CDMO services for protein-based therapeutics (such as mAb, BsAb), biosimilar, and bioconjugated drugs (such as XDCs/ADCs) from early-stage research through to commercial-scale manufacturing.

BioDlink operates large-scale biopharmaceutical manufacturing facilities compliant with GMP standards and adheres to international quality management systems aligned with regulatory requirements in the US, the EU, and China. With our cutting-edge technology platforms and expert teams, BioDlink facilitates accelerated development timelines, with clients spanning Europe, the Americas, Asia, and several key emerging markets.

BioDlink operates with a clear service philosophy: “Quality-Driven, Innovation-Enabled, Growth-Shared,” and has assembled an experienced and forward-thinking team. Committed to rigorous quality and compliance, the company nurtures a collaborative ecosystem that empowers its partners and delivers shared success. For more information, please visit: https://www.biodlink.com/

About Kexing Biopharm Co., Ltd.

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the integration of R&D, production and sales of recombinant protein drugs and microecological preparations. It focuses on antiviral, tumor and immune, blood, digestion, degenerative diseases and other therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of “innovation+internationalization”, At the same time, it explores the extensive application of biotechnology in the field of general health, actively cultivates and incubates new industries, the world’s leading industrial platforms such as animal vaccines and synthetic organisms have been distributed, and is committed to becoming a leader in high-quality biopharmaceutics and serving global patients.

Reference:

[1] Top three most populous countries in South America. https://en.wikipedia.org/wiki/List_of_South_American_countries_by_population

[2] Bevacizumab injection achieved global sales of USD 8.5 billion in 2023.

https://dataintelo.com/report/global-bevacizumab-injection-market

[3] Cancer incidence is rising sharply, especially colorectal cancer

https://www.sciencedirect.com/science/article/pii/S1936523321001662

[4] Combat colorectal and lung cancers, the top two leading causes of cancer-related deaths worldwide

https://www.who.int/news-room/fact-sheets/detail/lung-cancer

https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer

 

• New partnership set to cement Singapore as a global gaming and esports epicentre

SINGAPORE, Aug. 13, 2025 /PRNewswire/ — Competitive entertainment company BLAST has announced a landmark multi-year partnership with the Singapore Tourism Board (STB) to host four world-class arena esports events in Singapore over the coming years. This deal further highlights Singapore’s growing status as a premier destination for competitive gaming and live entertainment in Asia and globally.

The announcement follows the sellout success of the BLAST Premier World Final in 2024, which marked BLAST’s debut in Southeast Asia and saw a soldout Resorts World Convention Centre witness the best Counter-Strike teams in the world battle for a $1,000,000 prize pool.

Building on this momentum, BLAST is set to return to Singapore this November for the BLAST Dota Slam Singapore, the company’s first-ever Dota 2 arena event. Taking place at the Singapore Indoor Stadium from 7-9 November 2025, this tournament sets the stage for the newly signed multi-year partnership, which will bring four more premier esports arena events in Singapore after November’s Dota tournament.

The BLAST Dota Slam Singapore will feature the world’s top Dota 2 teams, a $1,000,000 USD prize pool, and an immersive live experience for local and international fans. The event will be broadcast in over 50 territories and 21 languages, reaching millions of viewers worldwide and further showcasing Singapore’s capability to host world-leading entertainment productions.

Leo Matlock, Chief Business Officer at BLAST, said: “BLAST has major global ambitions as a leader in esports and competitive entertainment and we are delighted to expand our partnership with Singapore.  Singapore delivered one of the most passionate and engaged esports crowds we’ve ever seen during last year’s BLAST Premier World Final Singapore 2024, was BLAST’s first event in South East Asia and thousands of passionate fans travelled from all over Asia and beyond. We are incredibly excited to be making a long-term commitment to the region through this new partnership with the Singapore Tourism Board. Together, we’ll bring four spectacular esports arena events to the Lion City, after this year’s Dota Slam. Singapore is already recognised as a hub for international sports and entertainment – this partnership will help ensure it becomes a leading destination in the global esports calendar, and is one of our biggest commitments to a market.”

Jean Ng, Assistant Chief Executive, Experience Development Group, Singapore Tourism Board, said: “Following the success of last year’s BLAST Premier World Final, we are delighted to forge this new multi-year partnership with BLAST that anchors a regular pipeline of esports events in Singapore and strengthens our position as Asia’s leading esports and entertainment hub. Large-scale international esports events create significant opportunities for our tourism ecosystem, benefiting local businesses and growing the local events and esports industries. We look forward to welcoming players and fans from around the world to Singapore this November and in the years ahead, where they can experience our vibrant culture and diverse offerings beyond the arena.”

The multi-year agreement is expected to generate tens of millions in economic impact for Singapore, through visitor spend, job creation, and international exposure. Esports fans, talent, media and commercial partners from across the world are anticipated to travel to the city for each event – transforming Singapore into a dynamic stage for esports’ biggest moments.

Singapore joins a global calendar that includes London, Lyon, Austin, Hong Kong and Rio, with the city-state’s position as an esports powerhouse in Asia only set to grow. This partnership reinforces how major esports tournaments are evolving into cultural and economic cornerstones, rivaling traditional international sporting events in scale, viewership and significance.

Fans can sign up at BLAST.tv to be the first to receive ticketing updates, exclusive news and access to future BLAST events in Singapore.

About BLAST

We’re on a mission to take esports to the next level of global entertainment. We excite and invite billions of fans to join the esports revolution. We create live and digital experiences – from tournaments that pack out major arenas around the world to great content that’s guaranteed to blow your socks off.

We are famous for our unparalleled production quality and game changing fan-first moments. Bringing together the best teams and biggest superstars to fight it out for glory and multi-million dollar prize pools. Attracting tens-of-thousands of fans to our crazy-big-adrenaline-pumped live events in big arenas from London and Lyon to Austin and Rio, with millions more watching at home from all around the world on our global broadcasts.

We work with some of the world’s best game publishers and brands to elevate their properties into amazing esports experiences. We are currently working with world-leading game publishers Epic Games, Valve and Ubisoft to produce, market and deliver esports for popular titles Rocket League, Fortnite, Rainbow Six, PUBG and Counter-Strike 2.

About AEG Presents

Combining the power of the live event with a focus on true artist development, AEG Presents is a world leader in the music and entertainment industries. Operating across four continents, the company has an unparalleled commitment to artistry, creativity, and community. Its tentpole festivals and multi-day music events — which include the iconic Coachella Valley Music & Arts Festival and the legendary New Orleans Jazz & Heritage Festival alongside American Express Presents BST Hyde Park, Stagecoach, Hangout Festival, Electric Forest, and Firefly — continue to set the bar for the live music experience. AEG Presents promotes global tours for artists such as The Rolling Stones, Elton John, Taylor Swift, Celine Dion, Justin Bieber, Kenny Chesney, Paul McCartney, and Katy Perry, in addition to — through its network of clubs, theatres, arenas, stadiums and renowned partner brands such as Goldenvoice, Messina Touring Group, Concerts West, The Bowery Presents, PromoWest Productions, Marshall Arts, Madison House Presents, and Zero Mile Presents — creating and developing an unmatched infrastructure for artist development and audience reach. More information can be found at www.aegpresents.com.

MINNEAPOLIS, Aug. 13, 2025 /PRNewswire/ — A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in the catheterization lab from scatter radiation. The findings show that while other next-generation systems offer protection for the primary operator and assistant, the EggNest™ Complete system provides significant protection for the entire interventional team.

The study, titled “Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems,” compared the EggNest™ Complete system with the Rampart IC system and a no-shielding condition using an anthropomorphic phantom. The results showed that both the EggNest™ Complete and Rampart IC systems significantly reduced radiation exposure for the operator and assistant positions compared to no shielding. However, the EggNest™ Complete system provided additional significant protection for staff at the head of the bed and the nursing positions, a benefit not observed with the Rampart IC system.

“From the beginning, Egg Medical has had three guiding principles: we need to protect the entire team from scatter radiation, we can’t interfere with workflow or patient access, and the reduction in radiation exposure must be nearly complete. The study by Riley et al shows very clearly that the EggNest Complete system dramatically reduces radiation exposure for everyone in the room, and that the operator and assistant are almost completely protected. That is a marked improvement to safety for everyone who works in x-ray guided procedures,” said Dr. Robert Wilson, CEO of Egg Medical.

The study’s authors note that interventional cardiology procedures expose healthcare professionals to prolonged ionizing radiation, which poses significant health risks including heightened rates of malignancy, cataracts, and orthopedic injuries. Traditional lead aprons, while offering some protection, are heavy (up to 25 pounds) and can lead to musculoskeletal injuries. A recent SCAI survey found that 66% of operators reported musculoskeletal pain attributed to their time in the cardiac catheterization laboratory.

“It’s a community effort to bring the issue of healthcare worker safety to the forefront of our industry. We deserve the same level of protection we strive to give to patients. This study highlights that Egg Medical’s EggNest Complete System sets a new standard for what ALARA (As Low As Reasonably Achievable) means today,” said Robert Riley, MD, a co-author of the study.

The study’s findings indicate that a comprehensive shielding system like EggNest™ Complete is crucial for ensuring the safety of all interventional lab personnel, including operators, assistants, nurses, and other staff. This is particularly important for complex procedures where staff may be positioned in areas with limited traditional shielding and higher cumulative exposure. The authors of a separate commentary on the study commended the findings, emphasizing that these results align with the Society for Cardiovascular Angiography & Interventions’ mission to advance occupational safety and are essential for sustaining the interventional cardiology workforce.

References

1. Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems. Stephen Kidd, MD, Robert F. Riley, MD, MS, Juliette Power, MD, Brian Stegman, MD, Thom G. Dahle, MD. Division of Cardiology, Overlake Medical Center, Bellevue, Washington. Division of Cardiology, St. Cloud Hospital, St. Cloud, Minnesota. Journal of the Society for Cardiovascular Angiography & Interventions (2025), doi:https://doi.org/10.1016/j.jscai.2025.103786
2. Is Egg Ready to Leave the Nest and Fly?, Journal of the Society for Cardiovascular Angiography & Interventions (2025), doi: https://doi.org/10.1016/j.jscai.2025.103863

About Egg Medical
Egg Medical is a global leader in radiation protection technologies. Headquartered in Minnesota, the company was founded with the goal to reduce the scatter radiation exposure of physicians, surgeons, nurses, technicians and others who use x-ray imaging to perform life-saving diagnostic and therapeutic procedures for patients. More information about Egg Medical is available at https://eggmedical.com.